CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use

Most people who choose CJC 1295 with DAC are making a completely logical trade: fewer injections for the same result. The problem is that the trade is not actually equal, and understanding why requires understanding what your pituitary is trying to do in the first place.

Your body does not release growth hormone in a steady stream. It releases it in pulses, sharp spikes that shoot up and then fall back down to near zero, and those valleys between pulses are not wasted time. They are part of how your tissues respond to the signal. The receptor that responds to growth hormone, and the receptor that responds to the releasing hormone that triggers it, both need a period of low exposure to reset and stay sensitive. Think of it like knocking on a door. If you knock, pause, knock again, someone answers. If you just lean on the doorbell continuously, eventually they stop answering. Your pituitary works the same way.

This is the system that CJC 1295 without DAC is designed to work inside of. It mimics something called GHRH, which is growth hormone releasing hormone, the signal your hypothalamus normally sends down to your pituitary to trigger a pulse. Without the DAC modification, CJC 1295 has a half life of about 30 minutes. You inject it, it triggers a pulse from your pituitary, and then it clears. Your natural pulses keep firing between doses on their own schedule, so the rhythm your body already uses stays mostly intact. You are amplifying the system without replacing it.

When you add DAC, the molecule changes in a specific way. DAC stands for drug affinity complex, and what it does is allow the peptide to bind to albumin, which is a protein that circulates in your blood and naturally has a much longer residence time than small unbound peptides. By hitching to albumin, CJC 1295 with DAC extends its half life from about 30 minutes to somewhere between 5.8 and 8.1 days. That is the range measured in a human clinical trial published in 2006.

The pituitary does not go silent with DAC. That same study showed that pulse frequency and pulse magnitude both stayed intact. So if you looked at a 24 hour growth hormone trace on DAC, you would still see spikes going up and coming back down, which is the part that makes it sound like everything is fine.

But the trough between those pulses, the baseline level that growth hormone falls back to between spikes, was elevated 7.5 times above normal. The valleys filled in. Instead of dropping back near zero between pulses, the baseline was now sitting at a chronically elevated level, and the pattern shifted from something that looked like distinct peaks over a quiet baseline to something that looked more like a continuous elevation with ripples on top.

That distinction matters more than it sounds. A study published in the Journal of Clinical Endocrinology and Metabolism in 2009 tested what happens when you deliver growth hormone to people in a pulsatile pattern versus a continuous one. They specifically measured lipolysis, which is the process of breaking fat down for energy, and the difference was not subtle. Pulsatile delivery brought lipolysis from a baseline of 4.1 up to 7.1 micromoles per kilogram per minute, almost double. Continuous delivery moved it from 4.1 to 4.8, a change so small it was not statistically different from doing nothing.

The growth hormone levels between the two groups were matched. Same total exposure. The only variable was the delivery pattern, and that pattern determined whether the fat burning response happened at all.

There is also a receptor level mechanism underneath this. When GHRH receptors on the pituitary are exposed continuously instead of in pulses, they start to downregulate, which means the cell reduces the number of functioning receptors on its surface. Research testing continuous GHRH exposure found that after just four hours, GHRH receptor messenger RNA dropped to 49 to 54 percent of baseline. That is roughly half the receptor expression gone in four hours of continuous stimulation. With DAC running at a 7 day half life, the pituitary is getting persistent low level GHRH signaling for a week at a time, which is exactly the condition that drives this receptor reduction.

So the picture with DAC ends up being: the trough between pulses is elevated, the fat burning advantage tied to pulsatile delivery disappears, and the receptors your body uses to respond to the signal are getting steadily downregulated during the entire cycle. You are using a secretagogue, but the property that makes secretagogues worth using over direct growth hormone is being systematically eroded.

That last point is worth sitting with. The reason someone reaches for a secretagogue instead of growth hormone is to work with the body's own rhythm and feedback machinery rather than overriding it. CJC 1295 without DAC does that. It inserts itself into the pulsatile system, amplifies it, and clears before it disrupts it. CJC 1295 with DAC turns the signaling into something closer to continuous elevation, and if continuous elevation is the goal, then growth hormone itself does that job with a known dose, a measurable blood level, and decades of clinical data. DAC leaves you in the middle: you have given up the pulsatile advantage of a secretagogue without gaining the precision of growth hormone.

The simpler version: if the pattern of delivery is what determines whether you actually get the benefit, then choosing a version of the peptide based on how often you inject is solving the wrong problem.

---

References

1. Surya S et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;948:2828-2834 — Pulsatile GH nearly doubled lipolysis 7.1 vs 4.1 baseline, continuous was not significantly different from baseline 4.8 vs 4.1. Source
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;9112:4792-4797 — CJC-1295 DAC preserved pulse frequency and magnitude but elevated basal trough GH 7.5-fold. Source
3. Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;913:799-805 — CJC-1295 DAC half-life 5.8-8.1 days due to albumin binding. Source
4. Aleppo G et al. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;1383:1058-1065 — Continuous GHRH exposure for 4 hours reduced GHRH receptor mRNA to 49-54% of baseline, dose-dependent and cAMP-mediated. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness